reports
LivaNova Reports First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis First-quarter U.S. GAAP...
Merit Medical Reports Results for First Quarter Ended March 31, 2024
Merit Medical Reports Results for First Quarter Ended March 31, 2024 Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023Q1 2024 non-GAAP EPS* $0.77, up 18.7%, compared to $0.64 in Q1 2023 * Constant currency revenue; constant currency revenu...
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company’s development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. “I am very pleased to welcome Ahmet to the LivaNova team. At...
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incide...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023. The incident resulted in a disruption to portions of the Company’s information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Com...
Amedisys Reports First Quarter 2024 Financial Results
Amedisys Reports First Quarter 2024 Financial Results BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-relat...
Chemed Reports First-Quarter 2024 Results
CINCINNATI--(BUSINESS WIRE)-- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2024, versus the comparable prior-year period. Changes to Non-GAAP Metrics Chemed uses certain non-GAAP metrics such as EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted earnings per share, to provide additional context ...
T2 Biosystems to Report First Quarter 2024 Financial Results and Busin...
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by a...
- Jonathan Moreland
MHLD MAIDEN HOLDINGS LTD.
HNRG HALLADOR ENERGY CO.
HOO HERBALIFE NUTRITION LTD.
DLTR DOLLAR TREE INC.
CRK COMSTOCK RESOURCES INC.
LULU LULULEMON ATHLETICA INC
RAIL FREIGHTCAR AMERICA INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
GLQ CLOUGH GLOBAL EQUITY FUND
WDFC WD-40 COMPANY
AINC ASHFORD
BRT BRT APARTMENTS
ISDR ISSUER DIRECT CORP.
LOVE LOVESAC
CWEN CLEARWAY ENERGY INC. CLASS C
ORGO ORGANOGENESIS HOLDINGS (A)
HROW HARROW HEALTH INC.
LEGH LEGACY HOUSING CORP
REEMF RARE ELEMENT RESOURCES
AIM AIM IMMUNOTECH
DCTH DELCATH SYSTEMS
HGBL HERITAGE GLOBAL
NKTX NKARTA
EGLE EAGLE BULK SHIPPING
SOWG SOW GOOD INC.
PHX PANHANDLE OIL AND GAS INC
SMMT SUMMIT THERAPEUTICS INC
AUID IPSIDY INC.
FSBC FIVE STAR BANCORP
DERM JOURNEY MEDICAL CORP
LEE LEE ENTERPRISES INC
MPA BLACKROCK MUNIYIELD PENNSYLVANIA FD
FTHY FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
TCBX THIRD COAST BANCSHARES INC
ASLE AERSALE CORP
AIKI AIKIDO PHARMA INC.
BUKS BUTLER NATIONAL CORP
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
NMAI NUVEEN MULTI-ASSET INCOME FUND
ACRV ACRIVON THERAPEUTICS INC
LSXMA LIBERTY SIRIUSXM GROUP
TISI TEAM INC.
CBSTF CANNABIST CO HOLDINGS INC.
TSVT 2SEVENTY BIO INC
ASGI ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
INTZ INTRUSION INC
PROP PRAIRIE OPERATING CO.
LGVN LONGEVERON INC
OCX ONCOCYTE CORPORATION
Edwards Lifesciences to Host Earnings Conference Call on April 25, 202...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart d...
- Jonathan Moreland
VITAS Completes the Previously Announced Purchase of Assets of Covenan...
CINCINNATI--(BUSINESS WIRE)-- VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE) announced the completion of the previously announced purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. d/b/a/ Covenant Care (“Covenant”) for an aggregate purchase price of $85 million. The transaction is structured as an asset purchase. Covenant’s hospice operations span the panhandle of Florida and Alabama, specifically including the Tallahassee, Marianna, Fort Walton Beach, Panama City, Crestvie...
- Jonathan Moreland
NEOG NEOGEN CORPORATION
MHLD MAIDEN HOLDINGS LTD.
HNRG HALLADOR ENERGY CO.
HOO HERBALIFE NUTRITION LTD.
GOGO GOGO INC.
DLTR DOLLAR TREE INC.
CRK COMSTOCK RESOURCES INC.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
LULU LULULEMON ATHLETICA INC
AAOI APPLIED OPTOELECTRONICS INC.
RAIL FREIGHTCAR AMERICA INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
GLQ CLOUGH GLOBAL EQUITY FUND
BRT BRT APARTMENTS
VICI VICI PROPERTIES INC
STKS THE ONE GROUP HOSPITALITY INC.
ISDR ISSUER DIRECT CORP.
CWEN CLEARWAY ENERGY INC. CLASS C
ORGO ORGANOGENESIS HOLDINGS (A)
HROW HARROW HEALTH INC.
LEGH LEGACY HOUSING CORP
REEMF RARE ELEMENT RESOURCES
AIM AIM IMMUNOTECH
DCTH DELCATH SYSTEMS
HGBL HERITAGE GLOBAL
NKTX NKARTA
EGLE EAGLE BULK SHIPPING
SOWG SOW GOOD INC.
PHX PANHANDLE OIL AND GAS INC
SMMT SUMMIT THERAPEUTICS INC
FSBC FIVE STAR BANCORP
DERM JOURNEY MEDICAL CORP
LEE LEE ENTERPRISES INC
ACHR ARCHER AVIATION INC
FTHY FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
TCBX THIRD COAST BANCSHARES INC
ASLE AERSALE CORP
AIKI AIKIDO PHARMA INC.
BUKS BUTLER NATIONAL CORP
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
NMAI NUVEEN MULTI-ASSET INCOME FUND
LSXMA LIBERTY SIRIUSXM GROUP
TISI TEAM INC.
CBSTF CANNABIST CO HOLDINGS INC.
TSVT 2SEVENTY BIO INC
ASGI ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
INTZ INTRUSION INC
PROP PRAIRIE OPERATING CO.
LGVN LONGEVERON INC
- Jonathan Moreland
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced results from the special meeting of stockholders on April 11, 2024. T2 Biosystems Stockholders voted for the approval of conversion of $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity. “We appreciate our stockholders demonstrating their continued support for the Comp...
- Jonathan Moreland
Chemed To Report First-Quarter 2024 Earnings April 24, Related Confere...
CINCINNATI--(BUSINESS WIRE)-- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday, April 25, 2024, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, or the hosting website . Participants may...
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supp...
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx® Instrument, ...
Chemed Corp: 2 directors
Two Directors at Chemed Corp sold/sold after exercising options 13,853 shares at between 643.140USD and 645.000USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the c...
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call. A live audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if dialing from outside the U.S.). The...
LivaNova Announces a Positive Predictive Outcome of Trial Success in i...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated. This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint. OSPREY is a prospective, multi-center, randomized controlled open-label trial demonstrating the safety and effectiveness of the aura6000™ Hypoglossal Nerve Stimulator System versus a no stimulation control in subjects with moderate to severe obstructive sleep ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.